Higher Medicine announces the formation of Higher Therapeutics, a wholly-owned, Delaware-based subsidiary dedicated to developing novel treatments for Friedreich’s ataxia (FA)—a progressive, inherited neurodegenerative disorder driven by mitochondrial dysfunction. Higher Therapeutics will lead the development of our p38 MAP kinase inhibitor program, a small-molecule approach designed to modulate cellular stress responses and restore mitochondrial health in patients with FA.

The creation of Higher Therapeutics marks a significant milestone in our long-term strategy to address multiple rare and complex diseases through focused therapeutic programs and broad funding bases. This dedicated structure allows each team to operate with clear disease-area alignment and tailored development priorities while remaining united under a shared scientific vision.

Higher Medicine will continue to advance its epigenetic discovery and development efforts for Kabuki Syndrome, a rare pediatric disorder caused by disrupted gene regulation. Our lead program—an LSD1 inhibitor—targets chromatin remodeling mechanisms that contribute to developmental delay and neurological symptoms in Kabuki Syndrome.

Together, Higher Medicine and Higher Therapeutics embody our dual mission: to deliver disease-modifying therapies for pediatric and neurodegenerative conditions with high unmet need, and to unlock the potential of epigenetic and mitochondrial medicine for patients across the lifespan.

We remain committed to advancing these programs into the clinic and forging partnerships that accelerate progress toward healthier futures for the communities we serve.